[Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
Some sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven their ability to reduce major cardiovascular events in patients with type 2 diabetes at high cardiovascular risk. Furthermore, SGLT2is reduce the risk of hospitalization for heart failure and the progression of renal disease. The 2018 ADA-EASD consensus gave the preference to either SGLT2is or GLP-1 RAs to prevent these complications. Underlying protective mechanisms are complex, differ between the two pharmacological classes and are potentially complementary, thus providing a rationale for a combination in patients at very high risk. Some studies already showed positive complementary effects on glucose control, body weight and arterial blood pressure, but not on cardiovascular and/or renal outcomes yet.